REGN5678

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Prostate CancerMetastatic Castration-Resistant Prostate Cancer, Mcrpc

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

1

Yervoy

Bristol-Myers Squibb

Phase 3

202

Cabometyx

Bristol-Myers Squibb

Phase 3

123

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

104

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

75

Lutetium Lu-177 PNT2002

JJonsson Comprehensive Cancer Center

Phase 3

46

Lhrha

Johnson & Johnson

Phase 3

27

Rhpsma-7.3 (18f)

BBlue Earth Diagnostics

Phase 3

48

HC-1119

HHinova Pharmaceuticals Inc.

Phase 3

29

Trexall

Jazz Pharmaceuticals

Preclinical

—10

REGN5678

Regeneron

Phase 2

3Show 22 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Prostate Cancer3 trials

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

Recruiting·Regeneron·Phase 1/2·NCT05125016·370 enrolled

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA X CD28) in Patients With High-Risk, Localized Prostate Cancer Followed by Radical Prostatectomy

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT06085664·42 enrolled

A Phase Ib Clinical Trial to Optimize Risk Benefit of REGN5678 (PSMAxCD28 Bispecific Antibody) Plus Cemiplimab (Anti-PD-1 Monoclonal Antibody) in Patients With Metastatic Castration-resistant Prostate Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06826768·60 enrolled

Metastatic Castration-resistant Prostate Cancer, mCRPC1 trial

A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression

Recruiting·Regeneron·Preclinical·NCT03972657·345 enrolled

Details

Drug Info

Related News